Treatment-resistant major depressive disorder
FBK-118 against placebo in treatment-resistant major depressive disorder. Sponsor: Fabrikam Neuroscience (fictional), CNS and psychiatry.
Which sites are ahead, on target or behind their expectation, where each loses its patients, and what might help.
Sites at a glance
Data to September 30th 2026. Sponsor: Fabrikam Neuroscience (fictional). Study-level KPIs and QTLs have their own tabs: KPIs and QTLs.
Patients randomised
0 of 243
0% of the target
Sites open
0 of 135
135 still to open
Patients screened
0
No change: +0 in the last three months
Sites behind their expectation
None judged
Every site is too early to judge: fewer than two patients expected so far
Agreed, of patients approached
0%
55% in published cancer trials
Randomised, of patients screened
0%
The plan assumed 43%
Are enough patients being screened?
No patient has been screened yet; the plan expects the first screens once sites open.
Screening has barely started
Patients screenedCumulative, against the screens the plan implies: its expected randomisations divided by the 43% it expects to pass screening
Show data
| Month | Planned | Actual |
|---|---|---|
| May 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Sources: epiClinical synthetic screening logs; screen failure by therapeutic area from the planner parameters (D23)
How each kind of site is doing
Each site is compared with what it was expected to recruit in its months open, given its type, track record, country and the protocol. Below 75% of that is behind; above 125% is ahead.
No site has been expected to recruit two patients yet, so none can be judged. The study is still in start-up.
Sites behind, and what might help
No site is behind its expectation.
Every site
Show all 135 sites
| Site | Profile | Months open | Expected | Randomised | Approached | Screened | Passed screening | Standing |
|---|---|---|---|---|---|---|---|---|
| 118-US-01, Denver | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-02, Baltimore | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-03, Nashville | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-04, Philadelphia | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-05, Minneapolis | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-06, Miami | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-07, Pittsburgh | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-08, Los Angeles | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-09, Charlotte | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-10, Boston | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-11, Atlanta | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-12, Chicago | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-13, Houston | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-14, San Diego | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-15, Dallas | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-16, Salt Lake City | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-17, Cleveland | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-18, New York | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-19, Phoenix | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-20, Seattle | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-21, Denver | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-22, Baltimore | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-23, Nashville | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-24, Philadelphia | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-25, Minneapolis | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-26, Miami | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-27, Pittsburgh | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-28, Los Angeles | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-29, Charlotte | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-30, Boston | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-31, Atlanta | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-32, Chicago | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-33, Houston | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-34, San Diego | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-35, Dallas | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-36, Salt Lake City | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-37, Cleveland | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-38, New York | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-39, Phoenix | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-40, Seattle | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-41, Denver | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-42, Baltimore | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-43, Nashville | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-44, Philadelphia | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-45, Minneapolis | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-46, Miami | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-47, Pittsburgh | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-48, Los Angeles | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-49, Charlotte | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-50, Boston | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-51, Atlanta | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-52, Chicago | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-53, Houston | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-54, San Diego | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-55, Dallas | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-56, Salt Lake City | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-57, Cleveland | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-58, New York | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-59, Phoenix | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-US-60, Seattle | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-01, Cambridge | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-02, Newcastle | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-03, Nottingham | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-04, Oxford | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-05, Leeds | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-06, Liverpool | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-07, Sheffield | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-08, Manchester | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-09, Birmingham | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-10, Southampton | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-11, Cardiff | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-12, Glasgow | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-13, Edinburgh | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-14, London | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-15, Bristol | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-16, Cambridge | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-17, Newcastle | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-18, Nottingham | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-19, Oxford | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-20, Leeds | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-21, Liverpool | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-22, Sheffield | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-23, Manchester | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-24, Birmingham | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-UK-25, Southampton | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-01, Granada | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-02, Madrid | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-03, Salamanca | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-04, Oviedo | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-05, Pamplona | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-06, Seville | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-07, Barcelona | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-08, Zaragoza | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-09, Valencia | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-10, Málaga | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-11, Bilbao | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-12, Alicante | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-13, Murcia | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-14, Santiago de Compostela | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-15, Córdoba | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-16, Granada | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-17, Madrid | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-18, Salamanca | Community specialist practice | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-19, Oviedo | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-20, Pamplona | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-21, Seville | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-22, Barcelona | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-23, Zaragoza | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-24, Valencia | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-ES-25, Málaga | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-01, Olsztyn | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-02, Bydgoszcz | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-03, Lublin | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-04, Białystok | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-05, Poznań | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-06, Łódź | Community hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-07, Wrocław | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-08, Zamość | Regional teaching hospital | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-09, Gdańsk | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-10, Rzeszów | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-11, Warsaw | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-12, Szczecin | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-13, Katowice | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-14, Kraków | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-15, Olsztyn | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-16, Bydgoszcz | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-17, Lublin | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-18, Białystok | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-19, Poznań | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-20, Łódź | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-21, Wrocław | Dedicated research centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-22, Zamość | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-23, Gdańsk | Academic medical centre | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-24, Rzeszów | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
| 118-PL-25, Warsaw | Site new to research | 0.0 | 0.0 | 0 | 0 | 0 | – | Too early |
Rules behind this page
- A site that has recruited below this share of its expected count is behind: 75%. epiClinical assumption, between the enrolment flag (0.8) and the point NCI trials rarely recovered from (0.6); about half of sites fall short of plan in practice (11% enrol nobody, 37% under-enrol; Tufts, register S-01).
- A site that has recruited above this share of its expected count is ahead: 125%. epiClinical assumption, set symmetrically to the behind line on a ratio scale (1 ÷ 0.8).
- Patients a site must have been expected to recruit before it is judged: 2. epiClinical assumption: below this, a site's count says more about chance than about the site.
- Patients offered a trial who agree to take part: 55%. 55.0% of patients offered a cancer treatment trial agreed, across 35 studies (Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155).
- Patients needed at a funnel stage before a site's rate there is compared with the study's: 8. epiClinical assumption: with fewer, a single patient moves the rate by more than ten points.
- A site's rate at a funnel stage is out of line when so poor a rate would happen by chance less often than this: 0.1. epiClinical assumption: a loose screen, because it prompts a look at the screening log rather than a judgement.
- Patients fail screening: Screen failure is high and varies widely by therapeutic area (register PM-05); restrictive criteria are the commonest design barrier (PB-02, PD-01).
- Patients wait too long for scans: epiClinical assumption from CRA practice; procedures per protocol rose 40.6% since 2010, which weighs on sites without services on site (register S-24).
- Too little coordinator time: Coordinator turnover of 10 to 37% a year, rising to 35 to 61% in 2022; 45% of sites say capacity limits new studies (register S-09, S-11).
- Competing trials take the same patients: Competing trials for the same patients reduce enrolment where the eligible pool is scarce (register EB-02, S-21).
- Too few patients referred: Research-focused sites recruit about 41% better, but depend on referral routes (register S-07); referral networks lack outcome evidence (action A14).
- Patients decline because of the journey: Procedural and visit burden lowers enrolment and retention (register PD-03); decentralised elements help mainly where travel is the barrier (PD-20).